Quadrivalent influenza vaccine shows immunogenicity and safety in Indian population aged 6 months and olderNew flu vaccine data shows strong immune response in Indian children and adults

This open-label phase III study investigated the immunogenicity and safety of a quadrivalent inactivated split-virion influenza vaccine (QIV) in an Indian population. The study enrolled 401 participants aged 6 months and older across five sites in India, with no comparator group beyond baseline immunogenicity values. Participants received the QIV according to standard age-appropriate dosing protocols, with immunogenicity and safety assessments conducted through day 29 post-vaccination.

The primary outcome was immunogenicity, measured by hemagglutination inhibition (HAI) geometric mean titers (GMTs) against all four vaccine strains. Results showed HAI GMTs increased from baseline across all age groups for all four influenza strains. However, the study did not report specific absolute numbers for these increases, nor did it provide effect sizes, confidence intervals, or p-values for these changes. The absence of these quantitative measures limits precise interpretation of the magnitude of immunogenic response.

Key secondary outcomes included HAI geometric mean titer ratios (GMTRs) and seroconversion rates. For GMTRs, the study found higher responses to A/H1N1 in adults aged 18 years and older compared to other age groups, while responses to A/H3N2 were similar across age groups. Younger participants demonstrated higher GMTRs for both B/Yamagata and B/Victoria strains. Seroconversion rates were generally highest against A/H1N1 across all ages. Again, the study did not report specific numerical values for these GMTRs or seroconversion rates, preventing quantitative assessment of these immunogenicity parameters.

Safety findings indicated the vaccine was generally safe and well tolerated in both adults and children. Solicited injection site reactions were comparable among age groups, with younger participants reporting fewer local reactions. No vaccine-related serious adverse events occurred during the study. The report did not specify rates of adverse events or provide data on discontinuations due to adverse events, limiting detailed safety assessment.

These results contribute to limited data on quadrivalent influenza vaccines in Indian populations. Prior landmark studies of influenza vaccines have typically been conducted in Western populations, making this study's focus on an Indian cohort particularly relevant for understanding vaccine performance in this specific demographic. The findings align with general expectations that quadrivalent influenza vaccines should induce immune responses against all four contained strains, though direct comparisons to other QIV formulations are not possible without specific immunogenicity data.

Methodological limitations include the open-label design without an active comparator, which introduces potential bias in safety assessments. The absence of reported absolute numbers, effect sizes, confidence intervals, and p-values for all immunogenicity outcomes significantly limits data interpretation. The relatively short 29-day follow-up period provides only immediate immunogenicity and safety data without longer-term durability information. The study's focus on immunogenicity rather than clinical efficacy endpoints means protection against actual influenza illness cannot be directly assessed.

Clinical implications suggest this quadrivalent influenza vaccine may be a viable option for influenza prevention in the Indian population aged 6 months and older, pending regulatory review. The immunogenicity data, while limited in quantitative detail, indicate the vaccine stimulates immune responses against all four strains. The safety profile appears acceptable with no vaccine-related serious adverse events reported. However, clinicians should interpret these findings cautiously given the methodological limitations and absence of detailed numerical data.

Unanswered questions include the precise magnitude of immunogenic response, durability of protection beyond 29 days, comparative effectiveness against other available influenza vaccines, and clinical efficacy against laboratory-confirmed influenza illness. The study also leaves unanswered questions about vaccine performance in specific high-risk subgroups within the Indian population and potential differences in immune response based on prior influenza vaccination history or exposure.